Optimizing the study design of clinical trials to identify the efficacy of artificial intelligence tools in clinical practices-Authors' reply

Ruiyang Li¹, Lanqin Zhao¹, Dongyuan Yun¹, Haotian Lin^{1

2}

Affiliations

¹ State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
² Center for Precision Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.

Ruiyang Li et al. EClinicalMedicine. 2019.

. 2019 Oct 24:16:12-13.

doi: 10.1016/j.eclinm.2019.09.010. eCollection 2019 Nov.

Ruiyang Li¹, Lanqin Zhao¹, Dongyuan Yun¹, Haotian Lin^{1

2}

¹ State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
² Center for Precision Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510080, China.

No abstract available

Conflict of interest statement

The authors declare no competing financial interests.

1. Lin H., Li R., Liu Z. Diagnostic efficacy and therapeutic decision-making capacity of an artificial intelligence platform for childhood cataracts in eye clinics: a multicentre randomized controlled trial. EClinicalMedicine. 2019;9:52–59. - PMC - PubMed
1. Hou Y., Wu X.Y., Li K. Issues on the selection of non-inferiority margin in clinical trials. Chin Med J (Engl) 2009;122(4):466–470. - PubMed
1. Sambucini V. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach. J Biopharm Stat. 2015;25(3):474–489. - PubMed
1. Rodger M., Ramsay T., Fergusson D. Diagnostic randomized controlled trials: the final frontier. Trials. 2012;13(1):137. - PMC - PubMed